SBIR/STTR Research Award
IGF OT IGF SBIR PHASE I TOPIC IMPROVING TARGETED CANCER THERAPIES BY MODULATING THE INTESTINAL MICROBIOME
Award amount
$268,641Program and phase
SBIR · Phase IAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- SYMBERIX, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- HN72U2V5AKN7
- Solicitation number
- Not reported
- Topic code
- NCI
Research abstract
A sugar scavenging bacterial enzyme glucuronidase bGUS in the GI microbiome is responsible for the dangerous diarrheal side effects of irinotecan an anti neoplastic agent used to treat advanced colorectal and pancreatic cancers Irinotecan which is rendered inactive in the liver by the attachment of a glucuronide sugar is reactivated by bGUS mediated cleavage of the glucuronide sugar in the lower GI microflora Reactivated irinotecan is highly toxic and damages nearby intestinal cells resulting in intense dose limiting diarrhea The goal of this project is to determine if bacterial bGUS which exists as a number of different enzyme orthologues in the GI microbiome is also involved in severe diarrheal side effects associated with another class of anti cancer drugs tyrosine kinase inhibitors TKIs
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Small molecule drugs targeting gut dysbiosis to manage inflammatory bowel disease
- Development of a companion diagnostic to identify patients who respond to microbiome-targeting drugs
- Developing novel inhibitors of the gut microbiome to modulate drug metabolism
- Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes
- Modulation of gut dysbiosis with Enterobacteriaceae-targeted antiproliferative agents to treat inflammatory bowel disease
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
12 SBIR/STTR records share this UEI (2014–2022). Reported award amounts total $7,360,599. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services